Molecular remissions are observed in chronic adult T cell leukemia/lymphoma in patients treated with mogamulizumab


Disclosures: This clinical trial was sponsored by Kyowa Kirin (Princeton, NJ). LBMC, GPT and AGR are supported by the National Institute for Health Research Imperial Biomedical Research Centre who also funded the molecular studies. AM, AW, JT and CRMB are supported by a Wellcome Investigator Award to CB.

Contributions: LBMC, AJM, PF and GPT recruited patients, and LBMC, JH, AJM, PF and GPT collected blood samples. MAD, SS, AW, JT, and AGR performed molecular assays of HTLV-1 proviral load and integration site mapping. RD performed the mutational analysis of CCR4, AGR performed the flow cytometry and AM, JT and AGR analyzed the HTLV-1 integration site mapping data. LBMC, CRMB, PF, GPT and AGR designed the study and wrote the paper.